.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The HIPARCO randomized clinical trial investigated whether treating obstructive sleep apnea with CPAP could improve blood-pressure control in patients with resistant hypertension. Adults receiving multiple antihypertensive medications were randomized to CPAP or no CPAP while continuing their usual cardiovascular therapy. After 12 weeks, CPAP was associated with a greater reduction in 24-hour mean blood pressure and diastolic blood pressure, along with improvement in the normal nocturnal blood-pressure dipping pattern. The degree of benefit was related to CPAP use, emphasizing adherence as an important determinant of effect. The study did not establish that CPAP eliminates the need for antihypertensive medication or that every patient with OSA will achieve a major blood-pressure reduction. Instead, it provides evidence that treating OSA can contribute to cardiovascular risk management, particularly in resistant hypertension. This directly matches NAPCON's sleep-medicine session on screening triggers beyond snoring, including resistant hypertension and diabetes. For pulmonologists and sleep physicians, the paper supports asking about OSA when hypertension is difficult to control and discussing CPAP as part of a broader multidisciplinary management strategy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HIPARCO randomized clinical trial investigated whether treating obstructive sleep apnea with CPAP could improve blood-pressure control in patients with resistant hypertension. Adults receiving multiple antihypertensive medications were randomized to CPAP or no CPAP while continuing their usual cardiovascular therapy. After 12 weeks, CPAP was associated with a greater reduction in 24-hour mean blood pressure and diastolic blood pressure, along with improvement in the normal nocturnal blood-pressure dipping pattern. The degree of benefit was related to CPAP use, emphasizing adherence as an important determinant of effect. The study did not establish that CPAP eliminates the need for antihypertensive medication or that every patient with OSA will achieve a major blood-pressure reduction. Instead, it provides evidence that treating OSA can contribute to cardiovascular risk management, particularly in resistant hypertension. This directly matches NAPCON's sleep-medicine session on screening triggers beyond snoring, including resistant hypertension and diabetes. For pulmonologists and sleep physicians, the paper supports asking about OSA when hypertension is difficult to control and discussing CPAP as part of a broader multidisciplinary management strategy.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
4 days back
